PMPC 2022 - 2022 International Conference on Personalized Medicine and Palliative Care
View: 495
Website http://www.pmpc.org.cn/ |
Edit Freely
Category cardiology; gastroenterology; geriatrics; neurology; oncology; paediatrics; primary care; psychiatry; psychology; renal medicine; respiratory medicine
Deadline: September 30, 2021 | Date: January 15, 2022-January 16, 2022
Venue/Country: Changsha, China
Updated: 2021-08-26 13:08:30 (GMT+9)
Call For Papers - CFP
With deeper understanding of pharmacogenomics, personalized medicine has become the strategy of the treatment of cancer and it was paied more and more attention. Especially, with the accomplishment of Human Genome Project, molecular medicine based on high-throughput experiments and new sequencing technologies is promising the development of personalized medicine. Meanwhile, many different categories of clinician and healthcare workers do clinical work associated with palliative medicine, specialist or generalist palliative care, supportive care, psychosocial-oncology and end of life care. PMPC 2022 provides a platform to bring together academic and clinical researchers, biotechnology, diagnostic and pharmaceutical companies, health professionals, regulatory and ethical experts, and government and regulatory authorities. We wish to engage specialties, not only those traditionally associated with personalized medicine and palliative care. This conference will promote innovative preclinical and translational scientific research and technologies related to personalized medicine, and extend the participants to doctors, nurses, other healthcare workers and researchers in medical and surgical specialties, including but not limited to cardiology, gastroenterology, geriatrics, neurology, oncology, paediatrics, primary care, psychiatry, psychology, renal medicine, respiratory medicine.Primary full-length articles with relevance to personalized medicine and palliative care will be considered for publication. The deadline for proposals is September 30th, 2021 by which all interested participants are required to submit a provisional title, full paper (4000-6000 words) and an indication of your willingness to participate. We highly encourage doctorate (PhD) and postgraduate students to present their research proposal or findings or issues in this conference with a very special registration fees.Accepted full papers will be published by SCITEPRESS (Science and Technology Publications) in Conference Proceedings and will be submitted to Ei, Scopus (Elsevier), dblp, Semantic Scholar, Google Scholar and Microsoft Academic for indexing.Topics of interest with a view towards personalized medicine and palliative care include (but are not limited to) the following:Regulation and bioethics in personalized medicinePharmacogenomics, genetics and biochemistry of drug uptake, action, and metabolismPersonalization of non drug related health intervention based on omicsOmics-based studies of disease risk, disease prognosis, and response to therapyNew therapies based on gene, nanotechnology and targeting strategyIntegration of drug target discovery and individualized treatmentGenome-wide association studies on complex diseases: progress, problems and future outlookGenetic testing, sequencing technologies, and molecular diagnosticsAdvancements in personalized medical technology and resourcesBioinformatics and health informaticsBiomarker of Effect and Risk AssessmentClinical rational administration and drug safetyDrug discovery process of genomics, proteomics and metabolomicsIf you have the idea of making our conference a vehicle for your research interests, please send your paper to the conference E-mail: pmpc2022migcca.com.Looking forward to seeing you in Changsha, and your support will be a great contribution to the successful meeting!
Keywords: Accepted papers list. Acceptance Rate. EI Compendex. Engineering Index. ISTP index. ISI index. Impact Factor.
Disclaimer: ourGlocal is an open academical resource system, which anyone can edit or update. Usually, journal information updated by us, journal managers or others. So the information is old or wrong now. Specially, impact factor is changing every year. Even it was correct when updated, it may have been changed now. So please go to Thomson Reuters to confirm latest value about Journal impact factor.